OMEGA PHARMA LIMITED
Get an alert when OMEGA PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£1M
+401.5% highest in 3 filed years
Net assets
£87M
+34.9% vs 2024
Employees
242
+9.5% highest in 3 filed years
Profit before tax
£30M
+0.6% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £188,770,000 | £262,990,000 | £325,284,000 | +23.7% | |
| Operating profit | £33,994,000 | £27,450,000 | £29,672,000 | +8.1% | |
| Profit before tax | £98,530,000 | £29,979,000 | £30,161,000 | +0.6% | |
| Net profit | £89,535,000 | £22,077,000 | £22,631,000 | +2.5% | |
| Cash | £595,000 | £206,000 | £1,033,000 | +401.5% | |
| Total assets less current liabilities | £92,884,000 | £66,430,000 | £87,525,000 | +31.8% | |
| Net assets | £92,758,000 | £64,835,000 | £87,466,000 | +34.9% | |
| Equity | £92,758,000 | £64,835,000 | £87,466,000 | +34.9% | |
| Average employees | 170 | 221 | 242 | +9.5% | |
| Wages | £12,043,000 | £17,368,000 | £13,211,000 | -23.9% | |
| Directors' remuneration | £587,000 | £580,000 | £758,000 | +30.7% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 18.0% | 10.4% | 9.1% | |
| Net margin | 47.4% | 8.4% | 7.0% | |
| Return on capital employed | 36.6% | 41.3% | 33.9% | |
| Gearing (liabilities / total assets) | 32.0% | 62.7% | — | |
| Current ratio | 3.07x | 1.59x | 2.19x | |
| Interest cover | 55.19x | 19.32x | 26.93x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- OMEGA PHARMA LIMITED 2012-10-05 → present
- CHEFARO UK LIMITED 2002-08-22 → 2012-10-05
- CHEFARO PROPRIETARIES LIMITED 1967-11-14 → 2002-08-22
Audit & accounting basis
- Accounting basis
- FRS 102
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period to 31 July 2027.”
Significant events
- “On 20 April 2022 the company was registered as guarantor to a fixed and floating loan facility granted by JP Morgan Chase Bank N.A.”
- “On 26 February 2026, the Company's ultimate parent undertaking, Perrigo Company plc, announced a group-wide restructuring programme to external markets as part of its fiscal year 2026 strategy.”
- “On 16 February 2026, the company surrendered an onerous lease relating to a warehouse building.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LORDEN, Bradley | Secretary | 2025-02-21 | — | — |
| DOHERTY, Sarah Jane | Director | 2025-02-03 | Feb 1984 | British |
| HOLLIES, Sonia Alexis | Director | 2024-07-08 | Oct 1969 | American |
| RUDD, Christopher Allan | Director | 2013-08-20 | Sep 1980 | British |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CORCORAN, Annette | Secretary | 2017-05-25 | 2025-02-21 |
| GALE, David Michael | Secretary | 1991-10-22 | 2008-05-07 |
| GILES, Alan Brantingham | Secretary | — | 1991-10-22 |
| KAVANAGH, Niall | Secretary | 2017-01-09 | 2017-05-25 |
| BATHURST, Nigel John | Director | 2009-10-05 | 2011-10-31 |
| COOL, Geert | Director | 2015-12-21 | 2016-10-28 |
| DE GANCK, David | Director | 2023-02-27 | 2024-07-08 |
| DEAN, Nigel Alan | Director | 1991-10-22 | 1993-08-31 |
| DOSE, Sheenagh | Director | 2018-04-03 | 2018-07-11 |
| GILES, Alan Brantingham | Director | — | 1991-10-22 |
| HOLME, Richard | Director | 2023-01-03 | 2024-03-31 |
| LISTER, Neil Thomas | Director | 2014-09-18 | 2023-01-03 |
| MILLS, Stuart Charles | Director | 2024-03-31 | 2025-08-31 |
| O'SULLIVAN, Patrick | Director | 2016-10-28 | 2018-04-03 |
| RIVERS, Dominic James | Director | 2018-04-03 | 2025-02-03 |
| SABBE, Sam Albert Camiel | Director | 2009-11-01 | 2012-01-05 |
| SCHEEPENS, Antonius Hendricus Johannus Maria | Director | 1996-04-22 | 2009-11-01 |
| STAEUBLE, Christoph Patrick | Director | 2011-11-01 | 2015-12-21 |
| VAN DONGEN, Caspar Franciscus Arnoldus Maria | Director | 1994-04-20 | 2009-10-05 |
| VANDENHEEDE, Griet Katleen | Director | 2012-01-16 | 2016-02-23 |
| VORSTMAN, Jan Geert | Director | — | 1996-01-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Perrigo Company Public Limited Company | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-07-03 | Active |
| Perrigo Pharma Holding (Nederland) Bv | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2024-07-03 |
Filing timeline
Last 20 of 177 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-24 | AA | accounts | Accounts with accounts type full | |
| 2025-09-02 | TM01 | officers | Termination director company with name termination date | |
| 2025-08-14 | AA | accounts | Accounts with accounts type full | |
| 2025-07-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-05-15 | CH01 | officers | Change person director company with change date | |
| 2025-03-07 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-03-07 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-02-24 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-21 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-24 | AA | accounts | Accounts with accounts type full | |
| 2024-07-18 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-18 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-07-03 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-07-03 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-04-15 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-12 | TM01 | officers | Termination director company with name termination date | |
| 2023-07-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-05-24 | AA | accounts | Accounts with accounts type full | |
| 2023-03-03 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.